# First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

> **NCT03015207** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 56 (actual)

## Conditions studied

- Metabolism and Nutrition Disorder
- Obesity

## Interventions

- **DRUG:** NNC0194-0499
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03015207
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-06
- **Primary completion:** 2017-10-26
- **Final completion:** 2017-10-26
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03015207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03015207, "First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03015207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*